Cecile Hillary Joins Sabin Foundation Europe Board of Trustees
LONDON — July 30, 2015 — Sabin Foundation Europe (SFE), the UK partner of the Sabin Vaccine Institute (Sabin), today announced the election of Ms. Cecile Hillary, managing director at Morgan Stanley and co-head of debt capital markets for financial institutions in Europe, to the SFE Board of Trustees.
Ms. Hillary is a founding member of the Sabin City Group, a collaborative partnership between SFE and corporate institutions in the UK. Established in late 2013, the Sabin City Group was designed to build a corporate stakeholder movement to raise the awareness, political will and funding necessary to control and eliminate the seven most common neglected tropical diseases (NTDs) by 2020.
“We are pleased to welcome Cecile Hillary as a member of our board following her years of service helping to lead corporate engagement for NTDs through the Sabin City Group,” said John Cummins, SFE chairman. “Her exemplary commitment, unique perspective, knowledge and passion for global health equity will be invaluable as we work together to combat vaccine-preventable and neglected tropical diseases.”
SFE, in partnership with the Sabin Vaccine Institute based in Washington, D.C., promotes proven, cost-effective solutions to the world’s most pervasive and often neglected health issues. It works to raise awareness and funding, particularly in the UK and across Europe, to combat vaccine-preventable and neglected tropical diseases. These diseases primarily afflict the world’s poorest people — those living on less than US $1.25 per day — whose health and economic well-being are often severely impacted.
“I am thrilled to join the Sabin Foundation Europe Board of Trustees,” said Ms. Hillary. “With more than 1.8 billion people at risk of NTDs, strong public-private partnerships will be critical to helping so many neglected communities around the world. I look forward to working with the SFE board to address these issues and mobilize the resources needed to reduce the global burden of NTDs.”
Prior to Morgan Stanley, Ms. Hillary worked at JPMorgan for 13 years in various roles, including securitization, capital markets, advisory and derivatives. She represents Morgan Stanley on the board of Opportunity Now, a gender diversity campaign that aims to increase women’s success in the workplace, and sits on the Morgan Stanley European Diversity Action Council. She graduated from the Institut d’Etudes Politiques in Paris (Sciences Po) and ESSEC business school in France.
About the Sabin Foundation Europe
Sabin Foundation Europe is a UK-registered charity founded in 2011 to support vaccine research and development, advocacy efforts and treatment programmes for vaccine-preventable and neglected tropical diseases. As a partner of the U.S.-based Sabin Vaccine Institute, Sabin Foundation Europe leads the efforts in the United Kingdom and across Europe to promote proven, cost-effective solutions to the world’s most pervasive, and least understood, health issues to policymakers, partners and other institutions. For more information, please visit www.sabin.org/sabin-foundation-europe.
About the Sabin Vaccine Institute
The Sabin Vaccine Institute (Sabin) is a non-profit, 501(c)(3) organization of scientists, researchers and advocates dedicated to reducing needless human suffering from vaccine-preventable and neglected tropical diseases (NTDs). Since its founding in 1993 in honor of Dr. Albert B. Sabin, the developer of the oral polio vaccine, Sabin has been at the forefront of global efforts to eliminate, prevent, and cure infectious and neglected tropical diseases.
Sabin develops new vaccines, advocates for increased use of existing vaccines and promotes expanded access to affordable medical treatments in collaboration with governments, academic institutions, scientists, medical professionals and other non-profit organizations. For more information, please visit www.sabin.org.